Announcement under Regulation 30 (LODR)-Press Release / Media Release
Dear Sirs, Sub: Glenmark Pharmaceuticals receives ANDA approval for Azelaic Acid Gel, 15% With reference to the subject mentioned above, kindly find attached media release which is self-explanatory. Request you to kindly take the same on record. Announcement under Regulation 30 (LODR)-Press Release / Media Release
Sub: Glenmark Pharmaceuticals Announces New Data Presentations on Ryaltris at the ACAAI Annual Scientific Meeting 2018 With reference to the subject mentioned above, kindly find attached media release which is self-explanatory. Glenmark gets USFDA nod for multiple sclerosis medication
Glenmark Pharmaceuticals on Thursday said it has received approval from the US health regulator for Teriflunomide tablets used to treat multiple scl Announcement under Regulation 30 (LODR)-Press Release / Media Release
Dear Sirs, Sub: Glenmark Pharmaceuticals receives ANDA approval for Teriflunomide Tablets, 7 mg and 14 mg With reference to the subject mentioned above, kindly find attached media release which is self-explanatory. Request you to kindly take the same on record. Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
We have to inform that the Nomination & Remuneration Committee of the Company, at its meeting held on November 13, 2018 has granted 20,000 stock options pursuant to Employee Stock Options Scheme, 2016 Outcome Of The Board Meeting - November 13, 2018
Ref.: Intimation under Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('LODR, 2015') Pursuant to Regulations 30 and 33 of the SEBI LODR, 2015, we wish to inform you that Board has today at its meeting approved the Unaudited Financial Results for the Second Quarter and Half Year ended September 30, 2018.... Glenmark to launch phase 1 trial in solid tumours for myeloma drug
Glenmark Pharmaceuticals on Thursday said it will launch phase 1 trial in solid tumours for its bispecific antibody GBR 1342, indicated for the trea Announcement under Regulation 30 (LODR)-Press Release / Media Release
Sub: Glenmark Pharmaceuticals Announces Decision to Launch Phase 1 Trial in Solid Tumors for its CD38xCD3 Bispecific Antibody GBR 1342 Based on Human Translational Data With reference to the subject mentioned above, kindly find attached media release which is self-explanatory. Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Enclosed please find herewith the details of Earnings Call slated for Wednesday, November 14, 2018 at 8:30 a.m. - 9:30 a.m. (IST), for your information and record. Please note that the recording of the call will be available on our website within 24 hours of the call. Closure of Trading Window
We have to inform you that, pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Tuesday, November 13, 2018, inter alia, to consider and approve the Unaudited Financial Results of the Company for the Second Quarter and Half Year ended September 30, 2018....